Soft Mist Inhalers Market Size is valued at USD 2.5 Bn in 2023 and is predicted to reach USD 4.1 Bn by the year 2031 at a 6.4% CAGR during the forecast period for 2024-2031.
A soft mist inhaler is a device designed to administer medication to the lungs in the form of a finely dispersed mist that moves slowly. This inhaler differs from standard inhalers in that it does not use a propellant or necessitate forceful inhalation. Instead, it generates a mist that is more easily inhaled, rendering it particularly beneficial for individuals with respiratory problems such as asthma or COPD. This device is portable, easy to use, and specifically engineered to effectively deliver medication to the lungs with reduced reliance on precise breathing techniques. Furthermore, the rising incidence of respiratory disorders such as congestive heart failure, cystic fibrosis, and asthma has led to a boom in the need for effective nebulizer inhalation devices, including soft mist inhalers (SMIs).
However, the market growth is hampered by the strict rules and regulations criteria for the safety and health of the soft mist inhalers market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high soft mist inhalers because Manufacturers of inhalers face difficulties in meeting regulatory requirements. Product approvals are slower and more expensive due to stringent standards for safety, effectiveness, quality control, and gadget performance, which slows down the market. Due to the COVID-19 pandemic, which has affected the worldwide market and forced the closure of numerous factories to protect their personnel from contracting the virus, the expansion of the industry may be hindered.
Competitive Landscape
Some Major Key Players In The Soft Mist Inhalers Market:
- Recipharm
- Boehringer, Ingelheim am Rhein, Germany
- Merxin Ltd
- DSB Medical Co., Ltd.
- Resyca BV
- Aero Pump GmbH,
- Ursatec GmbH
- 3M
- Other Prominent Players
Market Segmentation:
The soft mist inhalers market is segmented based on type, application type, age group, and end-user. Based on type, the market is segmented into disposable and reusable. By application type, the market is segmented into asthma, COPD, and others. By age group, the market is segmented into adults and paediatrics. The end-user market Comprises hospitals, clinics, and others.
Based On The Type, The Reusable Segment Is Accounted As A Major Contributor To The Soft Mist Inhalers Market.
The reusable soft mist inhalers market will hold a major global market share. Because they produce less waste than disposable inhalers, reusable inhalers align with the rising tide of sustainability and environmental awareness in healthcare. Reusable SMIs among both patients and healthcare professionals, which in turn led to their enormous expansion.
COPD Segment To Witness Growth At A Rapid Rate.
The rising incidence of respiratory ailments, including chronic obstructive pulmonary disease (COPD), and asthma, is propelling the need for efficient inhalation devices. As per the 2021 factsheet published by the World Health Organization, the global prevalence of asthma is estimated to impact 262 million individuals, while chronic obstructive pulmonary disease presents a substantial health obstacle as well.
In The Region, The North American Soft Mist Inhalers Market Holds A Significant Revenue Share.
The North American soft mist inhalers market is expected to record the maximum market revenue share in the near future. It can be attributed to the region's improved healthcare infrastructure and facilities, the high number associated with those suffering from asthma and COPD, cutting-edge medicines, influential figures, and increased healthcare spending. In addition, Europe is estimated to grow rapidly in the global soft mist inhalers market because of its large elderly population, rising standard of living, rising healthcare costs, and many developmental initiatives.
Recent Developments:
- In January 2024, Recipharm, a prominent CDMO, is pleased to announce a collaboration agreement and exclusive license with Medspray and Resyca to develop soft mist nasal administration devices for single and combination medication products.
Soft Mist Inhalers Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.5 Bn |
|
Revenue Forecast In 2031 |
USD 4.1 Bn |
|
Growth Rate CAGR |
CAGR of 6.4 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Application Type, Age Group, And End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Recipharm, Boehringer Ingelheim, Merxin Ltd, DSB Medical Co., Ltd., Resyca BV, Aero Pump GmbH, 3M and Ursatec GmbH. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
